Interactions between thrombophilic genetic mutations and clinical bleeding in patients on chronic oral anticoagulant treatment

Haematologica

Volumn 90, Issue 12, 2005, Pages 1720-1722

  Castori, Luigi ^a   Taliani, Maria Rita ^a   Agnelli, Giancarlo ^a   Boschetti, Enrico ^a   Gresele, Paolo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Bleeding; FV Leiden; Oral anticoagulant treatment; PT20210A mutation

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE MUTATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RISK ASSESSMENT; RISK FACTOR;

3' UNTRANSLATED REGIONS; ACENOCOUMAROL; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CASE-CONTROL STUDIES; FACTOR V; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; HEMORRHAGE; HOSPITALIZATION; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PREVALENCE; PROTHROMBIN; SAMPLE SIZE; THROMBOPHILIA; WARFARIN;

EID: 29144471067     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4.
2. Ferraresi P, Marchetti G, Legnani C, Cavallari E, Castoldi E, Mascoli F, et al. The heterozygous 20210 G/A prothorombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. Arterioscler Thromb Vasc Biol 1997;17:2418-22.
3. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996;348:423-8.
4. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3 untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88: 3698-703.
5. Cortelazzo S, Finazzi G, Viero P, Galli M, Remuzzi A, Parenzan L, et al. Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb Haemost 1993;69:316-20.
6. Melegh B, Stankovics J, Kis A, Nagy A, Storcz J, Losonczy H, Mehes K. Increased prevalence of factor V Leiden mutation in neonatal intracranial haemorrhage. Eur J Pediatr 1998;157: 261.
7. Aronis S, Bouza H, Pergantou H, Kapsimalis Z, Platokouki H, Xanthou M. Prothrombotic factors in neonates with cerebral thrombosis and intraventricular hemorrhage. Acta Paediatr Suppl 2002;438:87-91.
8. Petaja J, Hiltunen L, Fellman V. Increased risk of intraventricular hemorrhage in preterm infants with thrombophilia. Pediatr Res 2001;49:643-6.
9. D'Ambrosio RL, D'Andrea G, Cappucci F, Chetta M, Di Perna P, Brancaccio V, et al. Polymorphisms in factor II and FVII genes modulate oral anticoagulation with warfarin. Hematologica 2004;89:1510-6.
10. Nicolaes GA, Dahlback B. Factor V and thrombotic disease: description of a Janus-faced protein. Arterioscler Thromb Vasc Biol 2002;22:530-8.